NOVEL USE OF BCG IMMUNOGENIC FORMULATION EXPRESSING A HUMAN RESPIRATORY SYNCYTIAL VIRUS PROTEIN AGAINST HMPV IN CATTLE

摘要

The invention relates to the novel use of an immunogenic formulation containing the bacillus Calmette-Guérin (BCG) strain at a concentration between 104-109, which recombinantly expresses at least one protein or immunogenic fragment of human respiratory syncytial virus (RSV, Human orthopneumovirus), stabilised in a pharmaceutically acceptable saline buffer solution to prevent, treat or mitigate hMPV infections in cattle.